Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients

Journal of Medical Virology

Volumn 73, Issue 3, 2004, Pages 412-418

  Lilleri, Daniele ^a   Baldanti, Fausto ^a   Gatti, Marta ^a   Rovida, Francesca ^a   Dossena, Luca ^a   De Grazia, Simona ^a   Torsellini, Maria ^a   Gerna, Giuseppe ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amplicor CMV Monitor; Digene Hybrid Capture; HCMV antigenemia; Negative predictive value; Positive predictive value; Quantitative PCR

Indexed keywords

VIRUS DNA;

ARTICLE; CYTOMEGALOVIRUS INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CYTOMEGALOVIRUS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PREDICTION; RECIPIENT; SAFETY;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; VIREMIA;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 2542500693     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20107     Document Type: Article

References (31)

1. Boeckh M, Boivin G. 1998. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications Clin Microbiol Rev 11:533-554.
2. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. 1992. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 80:1358-1364.
3. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. 1996. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 88:4063-4071.
4. Britt WJ, Vugler L. 1987. Structural and immunological characterization of the intracellular forms of an abundant 68,000 Mr human cytomegalovirus protein. J Gen Virol 68:1897-1907.
5. Egan JJ, Lomax J, Barber L, Lok SS, Martyszczuk R, Yonan N, Fox A, Deiraniya AK, Turner AJ, Woodcock AA. 1998. Preemptive treatment for the prevention of cytomegalovirus disease. Transplantation 65:747-752.
6. Einsele H, Ehringer G, Steidle M, Vallbracht A, Muller M, Schmidt H, Saal JG, Waller HD, Muller CA. 1991. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 338:1170-1172.
7. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, Mackes P, Herter M, Klingebiel T, Loffler J. 1995. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86:2815-2820.
8. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. 2000. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032-2036.
9. Gerna G, Baldanti F, Sarasini A, Furione M, Percivalle E, Revello MG, Zipeto D, Zella D. 1994. Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. Antimicrob Agents Chemother 38:38-44.
10. Gerna G, Furione M, Baldanti F, Percivalle E, Comoli P, Locatelli F. 1995. Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. Br J Hematol 91:674-683.
11. Gerna G, Zavattoni M, Baldanti F, Sarasini A, Chezzi L, Grossi P, Revello M G. 1998a. Human cytomegalovirus (HCMV) leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 65:1378-1385.
12. Gerna G, Zavattoni M, Percivalle E, Grossi P, Torsellini M, Revello MG. 1998b. Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid organ transplant recipients with primary HCMV infection. J Clin Microbiol 36:1113-1116.
13. Gerna G, Baldanti F, Lilleri D, Parea M, Alessandrino E, Pagani A, Locatelli F, Middeldorp J, Revello MG. 2000a. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Microbiol 38:1845-1853.
14. Gerna G, Percivalle E, Baldanti F, Sozzani S, Lanzarini P, Genini E, Lilleri D, Revello MG. 2000b. Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events. J Virol 74:5629-5638.
15. Gerna G, Baldanti F, Lilleri D, Parea M, Torsellini M, Castiglioni B, Vitulo P, Pellegrini C, Vigano M, Grossi P, Revello MG. 2003a. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 75:1012-1019.
16. Gerna G, Lilleri D, Baldanti F, Torsellini M, Giorgiani G, Zecca M, De Stefano P, Middeldorp J, Locatelli F, Revello MG. 2003b. Human cytomegalovirus immediate early-mRNAemia vs. pp65-antigenemia for guiding pre-emptive therapy in children and young adults given hematopoietic stem cell transplantation: A prospective, randomized, open-label trial. Blood 101:5053-5060.
17. Gerna G, Sarasini A, Lilleri D, Percivalle E, Torsellini M, Baldanti F, Revello MG. 2003c. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J Infect Dis 188:1639-1647.
18. Grossi P, Minoli L, Percivalle E, Irish W, Viganò M, Gerna G. 1995. Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients. Transplantation 59: 847-851.
19. Hadaya K, Wunderli W, Deffernez C, Martin PY, Mentha G, Binet I, Perrin L, Kaiser L. 2003. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol 41:3757-3764.
20. Kusne S, Grossi P, Irish W, St George K, Rinaldo C, Rakela J, Fung J. 1999. Cytomegalovirus pp65 antigenemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus cytornegalovirus disease in adult liver transplant recipients. Transplantation 68:1125-1131.
21. Li H, Dummer JS, Estes WR, Meng S, Wright PF, Tang YW. 2003. Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients. J Clin Microbiol 41:187-191.
22. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B, Mattsson J, Sparrelid E, Winiarski J, Ringden O. 1998. Results of different strategies for reducing cytornegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66:1330-1334.
23. Locatelli F, Percivalle E, Comoli P, Maccario R, Zecca M, Giorgiani G, De Stefano P, Gerna G. 1994. Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone marrow transplantation: Role of early antiviral treatment for HCMV antigenaemia on patients' outcome. Br J Hematol 88:64-71.
24. Mengelle C, Pasquier C, Rostaing L, Sandres-Saune K, Puel J, Berges L, Righi L, Bouquies C, Izopet J. 2003a. Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia. J Med Virol 69:225-231.
25. Mengelle C, Sandres-Saune K, Pasquier C, Rostaing L, Mansuy JM, Marty M, Da Silva I, Attal M, Massip P, Izopet J. 2003b. Automated extraction and quantification of human cytomegalovirus DNA in whole blood by real-time PCR assay. J Clin Microbiol 41:3840-3845.
26. Nichols GW, Corey L, Gooley T, Drew WL, Miner R, Huang M-L, Davis C, Boeckh M. 2001. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 97:867-874.
27. Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF, Patel R, Jenkins G, Harmsen WS, Vanness DJ, Wiesner RH. 2002. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized placebo-controlled trial. J Infect Dis 185:854-860.
28. Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, Smith TF, Paya CV. 2002a. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant patients with CMV disease. Transplantation 73:968-973.
29. Razonable RR, Paya CV, Smith TF. 2002b. Role of the laboratory in the diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 40:746-752.
30. Revello MG, Zavattoni M, Percivalle E, Grossi P, Gerna G. 1989. Correlation between immunofluorescent detection of human cyto megalovirus immediate early antigens in polymorphonuclear leukocytes and viremia. J Infect Dis 160:159-160.
31. Van der Bij W, Schirm J, Torensma R, Van Son WJ, Tegzess AM, The TH. 1988. Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol 26:2531-2535.